China Resources Pharmaceutical Group Ltd
HKEX:3320
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.51
6.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
China Resources Pharmaceutical Group Ltd
Cash from Operating Activities
China Resources Pharmaceutical Group Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Cash from Operating Activities
HK$18.3B
|
CAGR 3-Years
39%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Cash from Operating Activities
HK$2.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
13%
|
|
|
S
|
SSY Group Ltd
HKEX:2005
|
Cash from Operating Activities
HK$785.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Cash from Operating Activities
¥2.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Cash from Operating Activities
¥6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
12%
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Cash from Operating Activities
-$47m
|
CAGR 3-Years
24%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
China Resources Pharmaceutical Group Ltd
Glance View
China Resources Pharmaceutical Group Ltd. is an investment holding, which engages in the research and development, manufacture, distribution, and retail of pharmaceutical and healthcare products. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The firm mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.
See Also
What is China Resources Pharmaceutical Group Ltd's Cash from Operating Activities?
Cash from Operating Activities
18.3B
HKD
Based on the financial report for Jun 30, 2024, China Resources Pharmaceutical Group Ltd's Cash from Operating Activities amounts to 18.3B HKD.
What is China Resources Pharmaceutical Group Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
18%
Over the last year, the Cash from Operating Activities growth was 82%. The average annual Cash from Operating Activities growth rates for China Resources Pharmaceutical Group Ltd have been 39% over the past three years , 18% over the past five years .
You don't have any saved screeners yet
